Cargando…

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

BACKGROUND: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Lopez, Jose P, Gonzalez, Ana Maria, Lanza, Paola, Lopez-Jaramillo, Patricio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504901/ https://www.ncbi.nlm.nih.gov/pubmed/37719697 http://dx.doi.org/10.2147/VHRM.S421024

Ejemplares similares

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
por: Lopez-Jaramillo, Patricio, et al.
Publicado: (2023)

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
por: Becerra, Virginia, et al.
Publicado: (2015)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2023)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke
por: Wald, Nicholas J., et al.
Publicado: (2016)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
por: Roy, Ambuj, et al.
Publicado: (2017)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
por: Jahangiri, Reza, et al.
Publicado: (2022)

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
por: Lafeber, M., et al.
Publicado: (2016)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Sukonthasarn, Apichard, et al.
Publicado: (2020)

Correction: Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
por: Jahangiri, Reza, et al.
Publicado: (2023)

Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients
por: Ros-Castelló, Victoria, et al.
Publicado: (2020)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
por: Cordero, Alberto, et al.
Publicado: (2023)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
por: Soliman, Elsayed Z, et al.
Publicado: (2011)

Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations—A Social Epidemiology Counterargument
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2020)

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
por: Wood, Frances, et al.
Publicado: (2015)

Medicinal herbs: Potential polypills in cardiovascular diseases
por: Noroozi, Samaneh, et al.
Publicado: (2021)

Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
por: Memon, Rahat A, et al.
Publicado: (2023)

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
por: Baumgartner, Ana, et al.
Publicado: (2020)

Could patents interfere with the development of a cardiovascular polypill?
por: Beall, Reed F., et al.
Publicado: (2016)

Redefining the polypill: pros and cons in cardiovascular precision medicine
por: Birla, Siddharth, et al.
Publicado: (2023)

The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials
por: Virk, Ghazala S, et al.
Publicado: (2023)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022)

The polypill approach – An innovative strategy to improve cardiovascular health in Europe
por: Fuster, Valentín, et al.
Publicado: (2017)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
por: Liu, Hueiming, et al.
Publicado: (2010)

A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
por: Sarfo, Fred Stephen, et al.
Publicado: (2023)

Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country
por: Yan, Lily D., et al.
Publicado: (2022)

The Polypill: From Promise to Pragmatism
por: Huffman, Mark D.
Publicado: (2015)

Polypill revisited – Unity in diversity
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2020)

Adoption and scale-up of the cardiovascular Polypill: a realist institutional analysis
por: Abimbola, Seye, et al.
Publicado: (2022)

Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept
por: Browne, J. L., et al.
Publicado: (2016)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
por: Jowett, Sue, et al.
Publicado: (2017)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
por: Virdee, Satnam K, et al.
Publicado: (2013)

Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study
por: Jamison, James, et al.
Publicado: (2016)

Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in Singapore: a qualitative study
por: Koh, Joel Jun Kai, et al.
Publicado: (2018)

Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review
por: Banerjee, Amitava, et al.
Publicado: (2016)

Correlation of polypill and blood pressure level: A systematic review of clinical trials
por: Omrani, Hamidreza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9arb678chm5td0eilhp3km4pma